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Purpose. We quantify the additional radiation exposure in terms of eﬀective dose incurred by patients in the CT portion of
SPECT/CT examinations. Methods. The eﬀective dose from a variety of common nuclear medicine procedures is calculated
and summarized. The extra exposure from the CT portion of the examination is summarized by examination and body part.
Two hundred forty-eight scans from 221 patients are included in this study. The eﬀective dose from the CT examination is also
compared to average background radiation. Results. We found that the extra eﬀective dose is not suﬃcient to cause deterministic
eﬀects. However, the stochastic eﬀects may be signiﬁcant, especially in patients undergoing numerous follow-up studies. The
cumulative eﬀect might increase the radiation exposure compared to patient management with SPECT alone. Conclusions. While
the relative increase in radiation exposure associated with SPECT/CT is generally considered acceptable when compared with
the beneﬁts to the patient, physicians should make every eﬀort to minimize this eﬀect by using proper technical procedures and
educating patients about the exposure they will receive.
1.Introduction
Sincetheintroductionofhelicalcomputedtomography(CT)
in the early 1990s, the rapid development of the technology
and capabilities of these scanners has accelerated the im-
plementation of many new clinical applications. One such
advantage is the hybrid imaging SPECT/CT system, which
is continuing to gain popularity in nuclear medicine and
cardiology facilities. The clinical advantages of SPECT/CT
compared to SPECT alone have been documented by several
authors [1–4]. Combined SPECT/CT systems allow the
sequential acquisition of anatomic and molecular data while
minimizing changes in patient position, improving attenu-
ation correction, and providing inherently coregistered an-
atomic images.
Although the technology clearly has its beneﬁts, new
developments in hybrid imaging technology, including com-
bining SPECT with multislice CT systems, result in com-
bining exposure levels for patients, a greater occupational
hazard to staﬀ from scattered radiation and the requirement
for increased shielding in a nuclear medicine department.
In general, eﬀective dose (E) for CT examinations can be
higher than most other diagnostic imaging modalities [5].
There is also a considerable choice of CT user-selectable
exposure factors resulting in a signiﬁcant variation in CT
dose to the patient. In addition, in a nuclear medicine facility
devoidofCTtechnologists,therecouldpotentiallybelimited
knowledge of CT techniques, clinical applications, and asso-
ciated dose consequences. In recent years the radiation dose
incurred by CT examinations has been a subject of much
concern; several authors have highlighted the need for dose
optimization in CT, speciﬁcally in paediatric patients [6–8].
According to 2006 data, approximately 62 million CT exami-
nationswereperformedinhospitalsandout-patientfacilities
in the United States [9], and the number of CTs continues to
grow by 10–15% per year [10]. Thus, CT will continue to
contribute to a signiﬁcant portion of the total collective dose
delivered to the public from medical procedures involving
ionizing radiation. This study aims to characterize the ad-
ditional radiation exposure associated with the CT portion2 International Journal of Molecular Imaging
Table 1:Wholebodyeﬀectivedoseasaresultoftheradiopharmaceuticaladministeredforarangeofroutinenuclearmedicineexaminations.
Study type Average radiopharmaceutical
activity (MBq)
Eﬀective dose per unit
activity (mSv/MBq) [11]
Average radiopharmaceutical
eﬀective dose (mSv)
67Gallium 370 0.1 37.0
99mTc-MDP 1110 0.0057 6.3
99mTc-MIBI parathyroid 925 0.009 8.3
111In-Octreotide 222 0.054 12.0
111In-WBC 18.5 0.36 6.7
Tc99mC e r e t e c 740 0.0093 6.9
131IU p t a k e 74 0.52 38.5
131IP o s t t h e r a p yS c a n 5550 0.52 2886.0
111In Chloride (ProstaScint) 222 0.15 32.4
of SPECT/CT for a selection of common nuclear medicine
procedures, to assist clinicians in meeting the guide lines
presented by the International Commission on Radiation
Protection [6] with respect to minimizing the eﬀective dose
necessary to achieve beneﬁcial results for the patient.
2.MaterialsandMethod
Patient data from a dual-headed SPECT unit with an inte-
grated 6-slice CT scanner (Symbia T6 E-Cam, Siemens Med-
ical Systems, Erlangen, Germany) is presented in this study.
ThisCT portion ofthissystemhasvariabletubecurrent(20–
345mA), slice thickness of 0.6–10mm, and rotational speed
of0.6–1.5secs.Thetubevoltagefortheclinicalportionofthe
acquisition was 130kVp.
Data from 248 scans, comprising 221 patients is pre-
sented in this study. The contribution of total eﬀective dose
imparted by the nuclear tracers for each patient was calcu-
lated by multiplying the average administered activity for all
patients by the “eﬀective dose per unit administered activity”
conversion factors listed in the International Commission on
Radiological Protection (ICRP) Publication 53 [11]a n d8 0
[12].
The eﬀective dose from the CT portion of the exam-
ination is calculated from the product of the dose length
product (DLP) and a body-region-speciﬁc conversion factor,
k (mSv mGy−1 cm−1), which takes into account the varying
biological sensitivities of diﬀerent organs as given in Table 3
of AAPM report 96 [8]. DLP is a patient-speciﬁc value deter-
mined by the scan length and the acquisition parameters;
it represents the total amount of radiation delivered in the
acquisition.
The CT scan was acquired immediately following com-
pletion of the SPECT study with the patient in the same
position to minimize motion errors. Acquisition of patient
examinations on the Symbia T6 were performed using a tube
current modulation system, Care Dose 4D (Siemens). CARE
Dose 4D adjusts the tube current over the patient’s z-axis
(one dimension) and in the x-axis and y-axis (three dimen-
sions) based on the topogram. Real-time four-dimensional
modulation is available during scanning and is controlled
by using feedback from the previous rotation to set the tube
current according to the attenuation measured at each tube
angle [13]. The intention of this modulation is to select the
a p p r o p r i a t et u b ec u r r e n tt oa c h i e v eap r e d e t e r m i n e dl e v e l
of image noise, independent of patient size and anatomic
conﬁguration.
In accordance with quality control (QC) regulations,
standard body and head CT phantoms are used to measure
the weighted computed tomography dose index (CTDIw)
on an annual basis. This parameter is then used to calculate
the CTDIvol, which is a measure of the average dose within
the scan volume to a standardized phantom. The DLP is
then calculated from the product of the CTDIvol and the
scan length. The phantoms employed in the QC are a 32cm
diameter CT body phantom and a 16cm CT head and neck
phantom; both phantoms are 15cm thick and are composed
of solid acrylic (Capintec, USA).
3. Results and Discussion
The QC phantom-measured DLP for head and body phan-
toms were in tolerance and compared well to the DLP dis-
played on the console postacquisition (body: −4.3%, head:
−1.6%).
Table 1 displays the whole body eﬀective dose as a result
of the radiopharmaceutical administered for a range of rou-
tine nuclear medicine examinations analyzed in this study.
Table 2 displays the average eﬀective dose for the CT portion
of the exam. Table 3 displays the average eﬀective dose for
the CT portion of the exam, based on the anatomical region
being scanned.
The purpose of the CT scan in a SPECT/CT system is
to provide improved attenuation correction and to obtain
precise anatomic localization of radiopharmaceutical distri-
butions. It is generally accepted that these objectives can be
achieved using CT scans with a much lower exposure level
than that of standard diagnostic CTs. The Symbia T6 is a
diagnostic-quality CT and as such has the capability of ac-
quiring scans in the exposure range of a standard diagnostic
CT. The values obtained on this system are similar to that of
a diagnostic CT. For SPECT/CTs with diagnostic CT capabil-
ities such as the Symbia T6, there is the risk that unnecessary
high levels of radiation will be used.International Journal of Molecular Imaging 3
Table 2: Average eﬀective dose for the CT portion of the routine nuclear medicine examinations.
Study type No. of patients Average eﬀective dose (mSv) Range eﬀective dose (mSv)
67Gallium 10 8.2 ±5.0 0.4–18.8
99mTc-MDP 17 3.8 ±3.9 0.2–12.4
99mTc-MIBI parathyroid 78 5.4 ±1.7 0.7–8.5
111In-Octreotide 47 .0 ±3.3 3.7–11.1
111In-WBC 46 .4 ±4.1 1.4–10.9
Tc99mC e r e t e c 21 5 .1 ±0.4 14.8–15.4
131IU p t a k e 35 5.6 ±2.8 0.5–12.3
131IP o s t t h e r a p yS c a n 32 6.8 ±3.1 1.1–12.8
111In Chloride (ProstaScint) 39 9.5 ±4.9 3.6–23.3
Table 3: The average eﬀective dose for the CT portion of the exam, based on the anatomical region being scanned.
CT scan region No. of scans CT ED (mSv) Average eﬀective dose from
a diagnostic CT [14]
Chest 40 7.4 ±2.77
Abdomen 41 8.6 ±4.68
Pelvis 67 6.1 ±2.06
Head 10 0.7 ±0.52
Neck 81 5.2 ±1.83
Head and neck 91 .2 ±0.7—
There are two possible explanations as to why the
SPECT/CTdoseissimilartothatofadiagnosticCT.Theﬁrst
could be that lower exposure levels are being employed, but
the ﬁeld of view of the SPECT/CT (∼40cm) is larger than
the standard diagnostic abdomen examination (∼25cm),
resulting in a larger volume of tissue being scanned. As the
SPECT and CT are acquired in succession, before the SPECT
is reconstructed and analyzed, it may not be possible to
optimize the CT scan region unless information pertaining
to the location of suspicious patient anatomy is available
prior to the scan. The lack of this information may result
in the acquired CT scan length to be, by default, similar in
length to that of the SPECT scan (40cm FOV). This could
result in organs being exposed unnecessarily.
Alternatively, even though dose modulation is employed
onthissystem,thetargetnoiselevelcouldbesetatalevelthat
resultsinahigheﬀectivemAsand“diagnostic”imagequality.
Suﬃcient localization information may be obtained with a
lower radiation dose to the patient. It may be possible to
increase the target noise level, thereby reducing the eﬀective
mAs for SPECT/CT examinations.
Table 4 displays the eﬀective dose for the SPECT portion
of the examination and the CT eﬀective dose. In general only
one CT per examination is preformed except in the case of
the ProstaScint examination, where the patient undergoes an
abdomenandapelvisCT.However,dependinguponvariable
clinical scenarios,some patients may undergomorethan one
SPECT/CT scan, either to image more than one part of the
body (e.g., chest and abdomen/pelvis) or to followup at later
time points in order to improve accuracy of scan interpreta-
tion.
Patient dose may be compared with background radi-
ation exposures from natural sources which in the United
States averages 3mSv per year [8]. In the results presented
in Table 5 the corresponding background radiation in years
is given for the average eﬀective dose for each SPECT/CT
procedure.
Theradiationdoselevelsmeasuredherearenotsuﬃcient
to result in deterministic eﬀects. The principal risks to pa-
tients at these dose levels are the stochastic process of carcin-
ogenesis and genetic eﬀects [15]. Hall and Giaccia estimate
that the risk of fatal cancers increases by 4% for every Sv
of total eﬀective dose received by a patient. For the Siemens
system, the increased risk of fatal cancer by the inclusion
of an abdomen CT is 0.03%. In the context of one study
this may not represent signiﬁcant carcinogenic risk, but, in
patients undergoing numerous follow-up studies, the cumu-
lative eﬀect could result in a signiﬁcant increase in radiation
exposure compared to patients previously managed with
SPECT alone. However, it is worth noting that before the
availability of SPECT/CT patients frequently have been sent
for additional radiological examinations (X-ray or CT) sub-
sequent to the SPECT examination; thus, additional radia-
tion exposure would have occurred in these cases as well.
If a diagnostic level CT is acquired during the SPECT/CT
examination, it may negate the need for a separate diagnostic
CT, if required.
The risk ﬁgures presented here only give an estimate
of the risk involved for the CT portion of the SPECT/CT
examination. The eﬀective dose metric is useful in compar-
ing dose from diﬀerent diagnostic procedures and for com-
paring radiation risks associated with diﬀerent technologies.4 International Journal of Molecular Imaging
Table 4: The percentage increase in the eﬀective dose by examination by including the CT.
Study type Average radiopharmaceutical
eﬀective dose (mSv) CT eﬀective dose (mSv) % increase in eﬀective dose
by the inclusion of the CT
67Gallium 37.0 8.2 22%
99mTc-MDP 6.3 3.8 60%
99mTc-MIBI parathyroid 8.3 5.4 65%
111In-Octreotide 12.0 7 58%
111In-WBC 6.7 6.4 96%
Tc99mC e r e t e c 6.9 15.1 219%
131IU p t a k e 38.5 5.6 15%
131IP o s t t h e r a p yS c a n 2886.0 6.8 <1%
111In Chloride (ProstaScint) 32.4 9.5 29%
Table 5: Eﬀective dose and equivalent background radiation for the total SPECT/CT eﬀective dose for each examination.
Study type Total eﬀective dose (mSv) Equivalent background radiation
(years)
67Gallium 45.2 15.1
99mTc-MDP 10.1 3.4
99mTc-MIBI parathyroid 13.7 4.6
111In-Octreotide 19.0 6.3
111In-WBC 13.1 4.4
Tc99mC e r e t e c 22.0 7.3
131IU p t a k e 44.1 14.7
131IP o s t t h e r a p yS c a n 2892.8 964.3
111In Chloride (ProstaScint) 41.9 14.0
However, in order to determine an accurate risk to any
individual the absorbed dose to irradiated tissues is the more
appropriate quantity.
4. Conclusion
Despite the advantages associated with SPECT/CT, questions
remain regarding its broad applicability to all traditional
SPECT applications. Physicians with hybrid cameras are
encouraged to carefully consider the risks and beneﬁts
associated with adding CT to their SPECT studies prior to
imaging a patient. Understanding the risks and beneﬁts of
SPECT/CT versus SPECT alone is important not only for
deciding on what type of scan to perform but also in order
to properly educate patients regarding the exposure they
will receive during a test. In general, the relative increase
in radiation exposure associated with SPECT/CT compared
to SPECT alone is considered acceptable given the potential
beneﬁts associated with this technique. However, every eﬀort
should be made to adhere to the “As Low as Reasonably
Achievable (ALARA)” principle and ensure that the patient
is not subjected to unnecessarily high levels of radiation.
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